Trabectedin - CAS# 114899-77-3 pone is an investigational drug for

is an investigational drug for the acute conversion of atrial fibrillation

a member of the inhibitor of apoptosis (IAP) gene family

A2764 dihydrochloride is a selective inhibitor of TRESK (KCNK18) with an IC50 value of 11

Oseltamivir phosphate-treated mice present significantly more inflammatory infiltrate in primary tumors (p=0

Trabectedin - CAS# 114899-77-3 pone is an investigational drug forTrabectedin (also known as ecteinascidin 743 or ET 743, trade name Yondelis) is an antitumor chemotherapy drug sold by Pharma Mar S. A. and Johnson and Johnson under the brand name Yondelis. It is approved for use in Europe, Russia, and South Korea for the treatment of advanced soft tissue sarcoma. It is also undergoing clinical trials for the treatment of breast, prostate, and paediatric sarcomas. The European Commission and the U. S. Food and Drug